293 related articles for article (PubMed ID: 31812593)
1. Cardiovascular biology of the GIP receptor.
Greenwell AA; Chahade JJ; Ussher JR
Peptides; 2020 Mar; 125():170228. PubMed ID: 31812593
[TBL] [Abstract][Full Text] [Related]
2. Human epicardial adipose tissue expresses glucose-dependent insulinotropic polypeptide, glucagon, and glucagon-like peptide-1 receptors as potential targets of pleiotropic therapies.
Malavazos AE; Iacobellis G; Dozio E; Basilico S; Di Vincenzo A; Dubini C; Menicanti L; Vianello E; Meregalli C; Ruocco C; Ragni M; Secchi F; Spagnolo P; Castelvecchio S; Morricone L; Buscemi S; Giordano A; Goldberger JJ; Carruba M; Cinti S; Corsi Romanelli MM; Nisoli E
Eur J Prev Cardiol; 2023 Jun; 30(8):680-693. PubMed ID: 36799940
[TBL] [Abstract][Full Text] [Related]
3. Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism.
Mroz PA; Finan B; Gelfanov V; Yang B; Tschöp MH; DiMarchi RD; Perez-Tilve D
Mol Metab; 2019 Feb; 20():51-62. PubMed ID: 30578168
[TBL] [Abstract][Full Text] [Related]
4. Effects on pancreatic Beta and other Islet cells of the glucose-dependent insulinotropic polypeptide.
Khan R; Tomas A; Rutter GA
Peptides; 2020 Mar; 125():170201. PubMed ID: 31751656
[TBL] [Abstract][Full Text] [Related]
5. Targeting the GIPR for obesity: To agonize or antagonize? Potential mechanisms.
Campbell JE
Mol Metab; 2021 Apr; 46():101139. PubMed ID: 33290902
[TBL] [Abstract][Full Text] [Related]
6. Loss of GIPR in LEPR cells impairs glucose control by GIP and GIP:GLP-1 co-agonism without affecting body weight and food intake in mice.
Akindehin S; Liskiewicz A; Liskiewicz D; Bernecker M; Garcia-Caceres C; Drucker DJ; Finan B; Grandl G; Gutgesell R; Hofmann SM; Khalil A; Liu X; Cota P; Bakhti M; Czarnecki O; Bastidas-Ponce A; Lickert H; Kang L; Maity G; Novikoff A; Parlee S; Pathak E; Schriever SC; Sterr M; Ussar S; Zhang Q; DiMarchi R; Tschöp MH; Pfluger PT; Douros JD; Müller TD
Mol Metab; 2024 May; 83():101915. PubMed ID: 38492844
[TBL] [Abstract][Full Text] [Related]
7. The role of GIP in α-cells and glucagon secretion.
El K; Campbell JE
Peptides; 2020 Mar; 125():170213. PubMed ID: 31785304
[TBL] [Abstract][Full Text] [Related]
8. Diabetes and obesity treatment based on dual incretin receptor activation: 'twincretins'.
Skow MA; Bergmann NC; Knop FK
Diabetes Obes Metab; 2016 Sep; 18(9):847-54. PubMed ID: 27160961
[TBL] [Abstract][Full Text] [Related]
9. The glucose-dependent insulinotropic polypeptide signaling axis in the central nervous system.
Adriaenssens AE; Gribble FM; Reimann F
Peptides; 2020 Mar; 125():170194. PubMed ID: 31697967
[TBL] [Abstract][Full Text] [Related]
10. Discovery of a potent GIPR peptide antagonist that is effective in rodent and human systems.
Yang B; Gelfanov VM; El K; Chen A; Rohlfs R; DuBois B; Kruse Hansen AM; Perez-Tilve D; Knerr PJ; D'Alessio D; Campbell JE; Douros JD; Finan B
Mol Metab; 2022 Dec; 66():101638. PubMed ID: 36400403
[TBL] [Abstract][Full Text] [Related]
11. Glucose-dependent insulinotropic polypeptide receptor null mice exhibit compensatory changes in the enteroinsular axis.
Pamir N; Lynn FC; Buchan AM; Ehses J; Hinke SA; Pospisilik JA; Miyawaki K; Yamada Y; Seino Y; McIntosh CH; Pederson RA
Am J Physiol Endocrinol Metab; 2003 May; 284(5):E931-9. PubMed ID: 12540373
[TBL] [Abstract][Full Text] [Related]
12. Inactivation of the Glucose-Dependent Insulinotropic Polypeptide Receptor Improves Outcomes following Experimental Myocardial Infarction.
Ussher JR; Campbell JE; Mulvihill EE; Baggio LL; Bates HE; McLean BA; Gopal K; Capozzi M; Yusta B; Cao X; Ali S; Kim M; Kabir MG; Seino Y; Suzuki J; Drucker DJ
Cell Metab; 2018 Feb; 27(2):450-460.e6. PubMed ID: 29275960
[TBL] [Abstract][Full Text] [Related]
13. Glucose-dependent insulinotropic polypeptide (GIP) and cardiovascular disease.
Heimbürger SM; Bergmann NC; Augustin R; Gasbjerg LS; Christensen MB; Knop FK
Peptides; 2020 Mar; 125():170174. PubMed ID: 31689454
[TBL] [Abstract][Full Text] [Related]
14. The GIP receptor displays higher basal activity than the GLP-1 receptor but does not recruit GRK2 or arrestin3 effectively.
Al-Sabah S; Al-Fulaij M; Shaaban G; Ahmed HA; Mann RJ; Donnelly D; Bünemann M; Krasel C
PLoS One; 2014; 9(9):e106890. PubMed ID: 25191754
[TBL] [Abstract][Full Text] [Related]
15. Regulation of energy metabolism through central GIPR signaling.
Liskiewicz A; Müller TD
Peptides; 2024 Jun; 176():171198. PubMed ID: 38527521
[TBL] [Abstract][Full Text] [Related]
16. GIP-derived GIP receptor antagonists - a review of their role in GIP receptor pharmacology.
Rosenkilde MM; Lindquist P; Kizilkaya HS; Gasbjerg LS
Peptides; 2024 Jul; 177():171212. PubMed ID: 38608836
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological characterization of mono-, dual- and tri-peptidic agonists at GIP and GLP-1 receptors.
Yuliantie E; Darbalaei S; Dai A; Zhao P; Yang D; Sexton PM; Wang MW; Wootten D
Biochem Pharmacol; 2020 Jul; 177():114001. PubMed ID: 32360365
[TBL] [Abstract][Full Text] [Related]
18. The influence of Glucose-dependent Insulinotropic Polypeptide (GIP) on human adipose tissue and fat metabolism: Implications for obesity, type 2 diabetes and Non-Alcoholic Fatty Liver Disease (NAFLD).
Thondam SK; Cuthbertson DJ; Wilding JPH
Peptides; 2020 Mar; 125():170208. PubMed ID: 31759125
[TBL] [Abstract][Full Text] [Related]
19. Disruption of GIP/GIPR axis in human adipose tissue is linked to obesity and insulin resistance.
Ceperuelo-Mallafré V; Duran X; Pachón G; Roche K; Garrido-Sánchez L; Vilarrasa N; Tinahones FJ; Vicente V; Pujol J; Vendrell J; Fernández-Veledo S
J Clin Endocrinol Metab; 2014 May; 99(5):E908-19. PubMed ID: 24512489
[TBL] [Abstract][Full Text] [Related]
20. Glucose-dependent insulinotropic polypeptide (GIP) receptor antagonists as anti-diabetic agents.
Gasbjerg LS; Gabe MBN; Hartmann B; Christensen MB; Knop FK; Holst JJ; Rosenkilde MM
Peptides; 2018 Feb; 100():173-181. PubMed ID: 29412817
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
